United States Patent 11,020,343: Naloxone Intranasal Formulation Claims, Patent Scope and Competitive Landscape

U.S. Patent No. 11,020,343 protects a specific method of treating opioid overdose with a high-concentration, low-volume intranasal naloxone formulation. The core combination is 100 μL per administration, 18-50 mg/mL naloxone HCl equivalent, aqueous delivery, pH of 5.5 or lower, and no permeability enhancer. The broadest practical claim covers 1.8-5.0 mg naloxone HCl equivalent per 100 μL actuation.

The patent is directed to method-of-use claims rather than a standalone composition or device. Its commercial relevance is highest for 4 mg/0.1 mL nasal sprays, including products that use approximately 40 mg/mL naloxone HCl equivalent.

What does U.S. Patent 11,020,343 cover?

U.S. Patent 11,020,343 covers intranasal administration of naloxone for opioid overdose or overdose symptoms using a defined aqueous formulation and dose volume.[1]

Claim element	Scope
Therapeutic use	Treatment of opioid overdosing or at least one symptom
Route	Intranasal
Administration volume	Exactly 100 μL
Active ingredient	Naloxone or a pharmaceutically acceptable salt
Concentration	18-50 mg/mL naloxone HCl equivalent in claim 1
pH	5.5 or lower
Vehicle	Aqueous application fluid
Permeability enhancer	Excluded
Dose per 100 μL	1.8-5.0 mg naloxone HCl equivalent
Dosage forms	Nasal spray, nasal mucoadhesive dosage form or mucosal atomizer device
Administration pattern	One nostril, two nostrils, or repeat dosing
Combination use	May be co-administered with intramuscular or intravenous naloxone

The claims require the combined presence of each material limitation. A nasal naloxone product outside the claimed concentration range, with a pH above 5.5, with a nonaqueous vehicle, or with a permeability enhancer would not literally satisfy claim 1.

The claims do not require a particular spray pump, nozzle geometry, excipient, preservative, buffer, particle-size distribution or pharmacokinetic profile. Those omissions broaden the potential formulation and device coverage within the claimed numerical boundaries.

How do the claims differ from one another?

Claims 1-10 are a dependent-claim structure that narrows or specifies the general method in claim 1. Claims 11-13 restate narrower method concepts in independent form.

Claim	Principal limitation	Commercial significance
1	18-50 mg/mL; pH ≤5.5; no permeability enhancer	Core broad claim
2	20-60 mg/mL	Numerically inconsistent with claim 1 above 50 mg/mL
3	30-50 mg/mL	Targets concentrated formulations
4	40 mg/mL	Directly covers 4 mg in 100 μL
5	Water or aqueous saline	Limits the vehicle
6	One or two dosing units based on nostril administration	Covers single- and dual-nostril use
7	Spray, mucoadhesive or mucosal atomizer	Broadens device and dosage-form embodiments
8	Naloxone is the only pharmaceutically active compound	Excludes combination-active formulations
9	Co-administration with IM or IV naloxone	Covers rescue protocols using multiple routes
10	Single 100 μL unit administered to one nostril	Closely aligned with single-spray products
11	Specified concentration values up to 50 mg/mL	Independent formulation-use claim
12	One-nostril administration plus optional repeat dosing	Covers repeat rescue dosing
13	Same basic method, using “consisting essentially of”	Potentially narrower than claim 12

What is the scope of claim 1?

Claim 1 is the principal enforceable platform claim. It requires:

A patient in need of opioid-overdose treatment.
Intranasal administration.
Administration of 100 μL.
Naloxone dissolved in an aqueous fluid.
A final concentration of 18-50 mg/mL naloxone HCl equivalent.
pH of 5.5 or lower.
No permeability enhancer.

At 18 mg/mL, the 100 μL dose contains 1.8 mg naloxone HCl equivalent. At 50 mg/mL, it contains 5.0 mg. A 40 mg/mL formulation contains 4.0 mg per 100 μL.

The claim is therefore not limited to a 4 mg product. It covers a concentration and volume band that includes 1.8 mg, 2 mg, 3 mg, 4 mg and 5 mg doses, provided the other limitations are met.

Does claim 2 expand the scope above 50 mg/mL?

Claim 2 recites 20-60 mg/mL but depends on claim 1, which requires 18-50 mg/mL. Under ordinary claim-dependency principles, the effective scope is generally the intersection of the two ranges, or 20-50 mg/mL.[2]

The language creates a drafting issue rather than a reliable extension to 60 mg/mL. A product at 55 or 60 mg/mL would not satisfy claim 1 and therefore would have a substantial defense to infringement of claim 2 as drafted.

What does claim 4 protect?

Claim 4 specifically covers a final concentration equivalent to 40 mg naloxone HCl per mL of aqueous application fluid. With a 100 μL dose, that equals 4 mg naloxone HCl equivalent.

This is the claim with the closest commercial alignment to 4 mg/0.1 mL intranasal naloxone products. A product using 4 mg in a 100 μL spray, aqueous formulation, pH no higher than 5.5, and no permeability enhancer would fall within the literal numerical limitations of claim 4, subject to the remaining method and treatment requirements.

What is the importance of claims 11-13?

Claims 11-13 are independently presented methods and may provide fallback positions if claim 1 is challenged.

Claim 11 recites concentrations of “20 mg, 30 mg or 40 mg ... and 50 mg.” That wording can be read as identifying discrete concentrations, although the final “and 50 mg” may also be a drafting error intended to describe a range. A court would assess the specification, prosecution history and ordinary meaning of the claim language.

Claim 12 adds administration to one nostril and optional repeat dosing until an effective systemic amount is reached. Claim 13 uses “consisting essentially of,” which generally permits unrecited components that do not materially affect the basic and novel characteristics of the claimed method, while excluding materially significant additional steps or active ingredients.

When does U.S. Patent 11,020,343 lose exclusivity?

The patent issued on June 1, 2021.[1] Its relevant priority date is March 30, 2015, and the international filing date appears to control the ordinary 20-year patent-term calculation for the PCT-derived U.S. case.[1,3]

Event	Date
Earliest claimed priority	March 30, 2015
U.S. patent grant	June 1, 2021
Nominal 20-year term from international filing	March 30, 2036
Expected term-end framework	2036, subject to patent-term adjustment or disclaimer

The exact expiration date should be determined from the USPTO patent-term calculation, including any patent-term adjustment, terminal disclaimer or statutory disclaimer. Patent expiration does not eliminate regulatory exclusivity or other unexpired patents covering a marketed product.

Is there FDA Orange Book exclusivity for this patent?

Patent 11,020,343 is a method patent. Orange Book listing depends on whether the patent is submitted for an approved NDA product and whether it claims the drug substance, drug product or an approved method of use under FDA listing standards.[4]

The existence of a granted patent does not itself establish an Orange Book listing. A company assessing generic entry must confirm the current FDA Orange Book entries for the relevant NDA and determine whether the patent is listed against the product.

For naloxone nasal sprays, the relevant products include NARCAN nasal spray and KLOXXADO nasal spray. Their FDA labels, NDA records and Orange Book patent listings must be evaluated separately because a patent may cover one sponsor’s product, a formulation, a method of use, or a device configuration without covering every naloxone nasal spray.[4-7]

What products and formulations could fall within the patent?

A product is at greatest literal infringement risk when it matches the following profile:

4 mg naloxone HCl equivalent per 100 μL;
aqueous solution;
pH at or below 5.5;
no permeability enhancer;
single-nostril administration;
treatment of opioid overdose;
naloxone as the only active pharmaceutical ingredient.

The table below illustrates representative scenarios.

Product configuration	Likely relationship to claim 1
4 mg/100 μL aqueous spray, pH 4.0, no enhancer	Strong literal overlap
2 mg/100 μL aqueous spray, pH 4.5, no enhancer	Within 18-50 mg/mL range
8 mg/100 μL aqueous spray, pH 4.5, no enhancer	Outside concentration range
4 mg/100 μL, pH 6.0	Outside pH limitation
4 mg/100 μL with a documented absorption enhancer	Outside express no-enhancer limitation
4 mg in 200 μL	Outside the 100 μL limitation
Dry-powder naloxone	Outside the aqueous-fluid limitation
Aqueous naloxone plus a second active compound	Potentially outside claim 8, but not necessarily claim 1
4 mg/100 μL administered with IV naloxone	Potentially covered by claim 9
4 mg/100 μL repeated in the same nostril	Potentially covered by claims 12 and 13

Does the patent cover a nasal device?

The patent does not claim a device in independent form. Claim 7 identifies a nasal spray, nasal mucoadhesive dosage form or mucosal atomizer device as a dosage-form limitation.

A pump or atomizer may be covered when used in the claimed treatment method. The patent does not automatically block manufacture or sale of an unfilled pump, generic atomizer or nasal-delivery component used for unrelated products.

Does the patent cover manufacturing methods?

The issued claims do not directly claim manufacturing steps, mixing order, filling, sterilization, pump assembly, container closure systems or quality-control methods. Manufacturing risk is indirect. A manufacturer may infringe if it supplies or uses a product in a manner that induces or contributes to performance of the claimed treatment method.

Separate manufacturing patents, device patents, trade secrets and regulatory controls may create additional barriers.

How does Patent 11,020,343 compare with NARCAN and KLOXXADO patent estates?

Patent 11,020,343 overlaps technically with the commercial design space for high-dose intranasal naloxone, but it is not equivalent to the entire patent estate for any particular product.

Issue	Patent 11,020,343	NARCAN nasal spray	KLOXXADO nasal spray
Active ingredient	Naloxone	Naloxone hydrochloride	Naloxone hydrochloride
Covered dose concept	1.8-5.0 mg per 100 μL under claim 1	4 mg per 100 μL product	8 mg per 100 μL product
pH limitation	≤5.5	Product-specific label specification	Product-specific label specification
Enhancer limitation	No permeability enhancer	Product-specific formulation	Product-specific formulation
Claim type	Treatment method	Product, formulation, use and device estate	Product, formulation, use and device estate
Direct numerical fit	Strong for 4 mg/100 μL	Strong technical overlap	Generally outside the 18-50 mg/mL range
FDA pathway	Patent status separate from approval	NDA 208411	NDA 212045

The 4 mg NARCAN product is the most obvious technical overlap because 4 mg in 0.1 mL corresponds to 40 mg/mL. KLOXXADO contains 8 mg in 0.1 mL, equivalent to 80 mg/mL, which is outside claim 1’s 18-50 mg/mL range.[5,6]

That does not make KLOXXADO risk-free. A product can avoid one patent while remaining exposed to other patents covering intranasal delivery, naloxone concentration, device architecture, formulation attributes or methods of treating opioid overdose.

Which companies and products create competitive patent risk?

The main commercial actors are:

Company	Product or role	Patent-landscape relevance
Emergent BioSolutions	NARCAN nasal spray	4 mg/0.1 mL commercial reference product; high technical overlap
Hikma Pharmaceuticals	KLOXXADO nasal spray	8 mg/0.1 mL product; high-dose design outside the core concentration range
Adapt Pharma and related entities	NARCAN development and commercialization history	Originator-related formulation and device rights
Purdue Pharma and Opiant-related entities	Intranasal naloxone technology and product rights	Important historical patent owners and litigants
Generic manufacturers	Potential ANDA applicants	Paragraph IV risk depends on listed patents and approved product scope

Patent ownership and product commercialization have changed through assignments, acquisitions and licensing. The current USPTO assignment record should be used to identify the legal owner of Patent 11,020,343, while the FDA’s Orange Book and NDA records determine product-linked listing status.[1,4]

What Paragraph IV challenges and litigation affect the patent?

A Paragraph IV certification is relevant only if Patent 11,020,343 is listed in the Orange Book for the referenced NDA. A generic applicant can certify that a listed patent is invalid, unenforceable or not infringed. The patent owner may then file suit under 21 U.S.C. §355(j), potentially triggering a 30-month stay of ANDA approval.[8]

The key litigation questions are:

Is Patent 11,020,343 listed against NARCAN or another approved naloxone nasal spray?
Does the proposed generic use a 100 μL actuation?
Is its final concentration within 18-50 mg/mL?
Is the formulation aqueous and at pH 5.5 or lower?
Does it contain a permeability enhancer?
Does the proposed labeling instruct treatment of opioid overdose using the claimed method?
Are claims 11-13 sufficiently definite and properly supported?

A generic applicant may pursue a non-infringement design by using an 8 mg/100 μL concentration, changing the actuation volume, changing pH, using a different dosage form, or including a qualifying absorption-enhancing excipient. Each design change carries formulation, safety, device, bioequivalence and regulatory consequences.

No biosimilar pathway applies. Naloxone hydrochloride is a small-molecule drug, so competitive products proceed through the ANDA pathway or, where applicable, a 505(b)(2) application rather than the biosimilar provisions of the Public Health Service Act.

How strong is the patent estate?

Patent 11,020,343 has moderate-to-strong value against a narrow commercial target and weaker value as a universal barrier to naloxone nasal competition.

Strengths

The claims combine measurable, objective parameters.
Claim 4 maps directly to a 4 mg/100 μL product.
The patent covers both formulation attributes and the therapeutic administration method.
The no-enhancer limitation may distinguish earlier intranasal naloxone approaches that relied on absorption enhancers.
Claims 12 and 13 address repeat dosing and one-nostril administration.

Vulnerabilities

The exact 100 μL limitation creates a design-around pathway.
The 18-50 mg/mL range excludes higher-dose products such as 8 mg/100 μL formulations.
The pH ceiling may be vulnerable to prior-art disclosures of acidic naloxone solutions.
Claim 2 contains an internal range conflict.
Claims 11-13 contain awkward concentration language that may create definiteness and construction disputes.
Method claims require evidence that the accused product is used, directed to be used, or intended to be used in the claimed overdose-treatment manner.
Patent validity may depend on written description, enablement, anticipation and obviousness challenges involving prior intranasal naloxone formulations.

The strongest enforcement position is likely against a 4 mg/0.1 mL aqueous nasal spray with acidic pH and no permeability enhancer. The weakest position is against a high-dose product above 50 mg/mL or a nonaqueous or enhancer-containing formulation.

What generic launch scenarios exist?

Launch strategy	Patent risk under 11,020,343	Regulatory and commercial effect
4 mg/100 μL, same formulation profile	High	Likely requires Paragraph IV strategy if listed
2 mg/100 μL	High to moderate	Still within claim 1
5 mg/100 μL	High	At upper boundary of claim 1
8 mg/100 μL	Lower under this patent	Must assess other patents and FDA requirements
4 mg/200 μL	Lower under literal claim scope	Device and clinical performance may change
pH above 5.5	Lower under literal scope	Tolerability and stability must be established
Permeability enhancer added	Lower under literal scope	Safety and regulatory burden increase
Dry powder	Lower under literal scope	Different product-development and approval pathway

The commercial value of the patent depends on whether the market standard remains 4 mg/0.1 mL. If 8 mg/0.1 mL products gain share, Patent 11,020,343 becomes less effective as a market-wide barrier because those products sit above the claimed concentration ceiling.

What geographic coverage does the patent provide?

The patent provides U.S. protection only. Foreign equivalents may exist in Europe and other jurisdictions, but each counterpart has its own claims, prosecution history, opposition risk, term and enforceability status.

A global freedom-to-operate review should separate:

U.S. method claims;
European national or unitary patent rights;
Canadian and Australian counterparts;
formulation and device patents;
regulatory exclusivity;
manufacturing and supply agreements;
assignment and licensing chains.

A U.S. patent does not prevent manufacture or sale outside the United States unless corresponding foreign rights exist.

Key Takeaways

U.S. Patent 11,020,343 is a method patent for intranasal naloxone treatment.
Its core requirements are 100 μL, aqueous naloxone, 18-50 mg/mL, pH no higher than 5.5 and no permeability enhancer.
The practical dose range is 1.8-5.0 mg per administration.
Claim 4 directly targets 40 mg/mL, equivalent to 4 mg in 100 μL.
A 4 mg/0.1 mL product presents the highest technical overlap.
An 8 mg/0.1 mL product is outside the core concentration range at 80 mg/mL.
Claim 2 appears internally inconsistent because its 20-60 mg/mL range depends on claim 1’s 18-50 mg/mL range.
The patent does not claim a standalone nasal device or manufacturing process.
Paragraph IV relevance depends on Orange Book listing against a specific NDA.
Naloxone generics are not biosimilars and generally use the ANDA pathway.
The patent’s commercial strength is concentrated around 4 mg/0.1 mL products rather than the entire intranasal naloxone market.

FAQs About U.S. Patent 11,020,343

Does Patent 11,020,343 cover Narcan 4 mg nasal spray?

The claimed parameters materially overlap with a 4 mg/0.1 mL aqueous naloxone spray, particularly if the product has a pH of 5.5 or lower and no permeability enhancer. Product-specific infringement requires analysis of the approved formulation, instructions for use and patent ownership.

Does Patent 11,020,343 cover Kloxxado 8 mg?

The 8 mg/0.1 mL strength equals approximately 80 mg/mL, outside claim 1’s 18-50 mg/mL range. Other patents may still affect KLOXXADO or an equivalent generic product.

Can a generic avoid the patent by using 200 μL instead of 100 μL?

A 200 μL administration would not literally meet the express 100 μL limitation. The generic would still need to evaluate other patents and potential equivalents arguments.

Is pH 5.5 included in the claims?

Yes. The limitation “pH of ≤5.5” includes pH 5.5 and all lower pH values.

Does adding a second active ingredient avoid all claims?

No. It may avoid claim 8, which requires naloxone to be the only pharmaceutically active compound. Claims 1, 4, 11, 12 and 13 do not uniformly impose that single-active-ingredient limitation.

References

United States Patent and Trademark Office. (2021). U.S. Patent No. 11,020,343, Intranasal naloxone formulations.
United States Code, 35 U.S.C. §112.
United States Code, 35 U.S.C. §154.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2023). NARCAN naloxone hydrochloride nasal spray prescribing information. Emergent BioSolutions.
U.S. Food and Drug Administration. (2023). KLOXXADO naloxone hydrochloride nasal spray prescribing information. Hikma Pharmaceuticals.
U.S. Food and Drug Administration. (2015). NARCAN nasal spray, NDA 208411 approval materials.
United States Code, 21 U.S.C. §355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harm Reduction Therp	RIVIVE	naloxone hydrochloride	SPRAY, METERED;NASAL	217722-001	Jul 28, 2023		OTC	Yes	Yes	11,020,343	⤷ Start Trial				USE OF INTRANASAL NALOXONE FOR THE TREATMENT OF OPIOID OVERDOSE	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	086391	⤷ Start Trial
Austria	16553	⤷ Start Trial
Australia	2012257785	⤷ Start Trial
Australia	2016204880	⤷ Start Trial
Brazil	112013029126	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,020,343

Which drugs does patent 11,020,343 protect, and when does it expire?

Summary for Patent: 11,020,343